About RSRT
Our singular goal is to find cures for Rett syndrome as efficiently and quickly as possible. We will not rest until our children have them.
For us it’s personal. Our Chief Executive Officer and Chief Development Officer have a child with Rett. Twelve of our board members have a child, grandchild, or sibling with Rett. We are driven by the most profound motivator — love for our children and an unwavering commitment to change their lives and the lives of all with Rett.
Our Track Record
Speaks for Itself
From establishing various crucial consortia to identifying and funding cutting-edge research with a fearless vision for innovation, RSRT has been at the forefront of every valuable advancement toward accelerating cures for Rett syndrome.
Our scientific team has over 80 years of combined
experience in drug development and clinical trials.
Our Staff
Translational Medicine Advisory Board
Board of Trustees
The RSRT Ambassador Program welcomes parents and caregivers who share our excitement and commitment to accelerating cures for Rett syndrome. As compassionate liaisons with the Rett community, our Ambassadors share research updates, offer helpful information, and play a vital role in boosting our fundraising efforts. Together, we can make a meaningful impact in advancing scientific research!
Latest News
Summit 2025
Over the course of three days in September we convened leading scientists, clinicians, and regulators to explore every corner of the genetic medicines landscape. The leadership from over 45 biopharma companies had a unique opportunity to hear about the state of Rett genetic medicine programs, with the ultimate goal of inspiring and motivating them to add the disorder to their pipelines.
This year’s gathering underscored RSRT’s role as both convener and catalyst, bringing brilliant minds together while never losing sight of the children and families at the heart of our community.
Built on decades of scientific advances Roadmap to Cures will select and drive three genetic medicines that attack the root cause of Rett syndrome to clinical trials by 2028.
